Edwards-JenaValve deal better for patients, companies argue in post-trial brief
Edwards Lifesciences and JenaValve Technology submitted a post-trial brief Friday, arguing that their transaction is the best way forward for the companies and patients. The companies maintain that the US Federal...To view the full article, register now.
Already a subscriber? Click here to view full article